This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Top Research Reports for JPMorgan, American Express & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), American Express (AXP) and FedEx (FDX).
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
CVS Health's Aetna Deal Imminent, PBM Selling Season Strong
by Zacks Equity Research
CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
Should You Buy Walgreens Boots (WBA) Stock Ahead of Q4 Earnings?
by Benjamin Rains
Walgreens Boots Alliance (WBA) shares have surged 17% in the last three months to outpace the S&P 500's roughly 7% climb as fears that Amazon's (AMZN) pharmaceutical push would doom the pharmacy giant prove overblown. Now the question is should investors consider buying WBA stock ahead of its Q4 earnings release on October 11?
Top Research Reports for Adobe, United Technologies & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), United Technologies (UTX) and Lockheed Martin (LMT).
Here's Why You Should Invest in CVS Health (CVS) Stock Now
by Zacks Equity Research
CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.
Is CVS Health (CVS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna Gets Merger Nod, Forms Management for Unified Entity
by Zacks Equity Research
Cigna (CI) forms management as it prepares for new merged entity.
WellCare Health's (WCG) Buyout to Expand Medicare Business
by Zacks Equity Research
WellCare Health's (WCG) impending buyout of Aetna's Medicare business to expand and cement its foothold in the rapidly growing market.
Aetna a Step Closer to CVS Merger, Sells Medicare Business
by Zacks Equity Research
Aetna (AET) gets a step closer to its merger with CVS Health by selling its Medicare business to WellCare Health.
Are M&As Helping U.S. Markets Amid Trade War Fears?
by Ritujay Ghosh
This year so far has already seen quite a few big acquisitions, which is helping the broader market.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
Cigna Moves Closer to Express Scripts Buyout With DoJ Nod
by Zacks Equity Research
Cigna (CI) clears a significant regulatory hurdle with regards to its proposed acquisition of Express Scripts.
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
by Zacks Equity Research
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
Top Stock Reports for JPMorgan, Mastercard & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV).
CVS Health (CVS) Up 10.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Services Boom Drives Healthcare: 3 Top Picks
by Sreyoshi Mukherjee
Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.08, moving +0.58% from the previous trading session.
Are M&As the Secret Mantra Propelling US Markets' Bull-Run?
by Ritujay Ghosh
Given the bullish economic outlook, robust corporate earnings and interest rates still remaining low in the United States, companies are going for mergers for future growth.
Pharmacies and Drug Stores Stock Outlook: Prospects Bright
by Zacks Equity Research
Amazon's entry into drug distribution is expected be a game changer but the immediate implications will be limited, given that the healthcare space is highly complex and regulated.
Walmart Soared, But Amazon (AMZN) Stock Is Still a Must Buy
by Benjamin Rains
Walmart (WMT) saw its stock price surge over 10% Thursday after the retail giant reported stronger-than-anticipated quarterly financial results. Yet, while some investors dive into WMT stock, the e-commerce powerhouse that forced Walmart to revamp its business model seems as strong as ever. So let's see why Amazon (AMZN) stock looks like a great buy right now.
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
UnitedHealth to Spread in Pharmacy Business With Genoa Deal
by Zacks Equity Research
UnitedHealth's (UNH) acquisition of Genoa Health should aid the company's Optum segment.